Recent follow-up of targeted agents in patients with pulmonary hypertension
Objective To explore the clinical characteristics of patients with pulmonary hypertension treated in pulmonary hypertension treatment center,observe the efficacy of targeted drug therapy,and analyze the risk factors of cardiovascular adverse events in patients with pulmonary hypertension.Methods A retrospective study was con-ducted to collect 124 patients with pulmonary hypertension who were hospitalized for the first time in the Affiliated Hospital of Xuzhou Medical University and the First Affiliated Hospital of Chongqing Medical University from January 2016 to February 2021.The clinical characteristics,main etiology and first symptoms of the patients were analyzed.The overall effect of targeted drug therapy was observed.Summarize the occurrence of cardiovascular adverse events and analyze the risk factors.Results Mainly female patients,103 cases(83.1％),and the median age of onset was 38.0(27.5,51.0)years.Dyspnea was the most common first-episode symptom(85.0％).Pulmonary arterial hypertension related to congenital heart disease accounted for the highest proportion(49.2％).The 38-year-old group had poor cardiac function and high level of brain natriuretic peptide(P＜0.05).With type 5 phosphodiester-ase inhibitor+endothelin receptor antagonist was the most common(88％),and the proportion of high-risk patients was significantly decreased.Conclusion Pulmonary hypertension is more common in women,and the heart function deteriorates with age.Pulmonary hypertension related to congenital heart disease is more common,and the targeted drug therapy has a remarkable effect,and the 1-year survival rate is significantly improved.Cardiac index is a protec-tive factor in patients with pulmonary hypertension.
万方数据
维普
